BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vemzatatug vedotin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Vemzatatug vedotin\, from ClinicalTrials.
 gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06106945-3333@assetmemo.bio
DTSTAMP:20261121T010442Z
DTSTART;VALUE=DATE:20280124
DTEND;VALUE=DATE:20280125
SUMMARY:Vemzatatug vedotin: Phase 1/2 readout est. (NCT06106945)
DESCRIPTION:Vemzatatug vedotin\, phase 1/2\, Multiple Myeloma.\nStudy: AZD0
 305 as Monotherapy or in Combination With Anticancer Agents in Participant
 s With Multiple Myeloma\nEstimated primary completion: 24 January 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/vemzatatug-vedotin#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06106945
URL:https://assetmemo.bio/drug/vemzatatug-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
